Acquired and hereditary forms of recurrent angioedema: Update of treatment

作者：Bork K^*

来源：Allergologie, 2013, 36(3): 108-119.

DOI：10.5414/ALX01561

• angioedema
• hereditary angioedema
• C1 esterase inhibitor deficiency
• bradykinin
• C1-INH concentrate
• bradykinin B2 receptor antagonist

Acquired and hereditary forms of recurrent angioedema: Update of treatment The aim of treatment of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (HAE-C1-INH) is either treating acute attacks or preventing attacks by using prophylactic treatment. For treating acute attacks, plasma-derived C1 inhibitor (C1-INH) concentrates, a bradykinin B2 receptor antagonist, and a recombinant human C1-INH are available in Europe. In the United States, a plasma-derived C1-INH concentrate, a bradykinin B2 receptor antagonist, and a plasma kallikrein inhibitor were approved for the treatment of acute attacks. Fresh frozen plasma is also available for treating acute attacks. Short-term prophylactic treatment focuses on C1-INH and attenuated androgens. Long-term prophylactic treatments include attenuated androgens such as danazol, stanozolol, and oxandrolone, antifibrinolytics, and a plasma-derived C1-INH concentrate. Plasma-derived C1-INH and a bradykinin B2 receptor antagonist are admitted for self-administration and home therapy. So the number of management options increased considerably within the last few years thus helping to diminish the burden of HAE.

• 出版日期2013-3